Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.
Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.
Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.
Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will participate in the 2023 ICR Conference, hosting a fireside chat on January 10, 2023, at 2:30 p.m. ET. Interested parties can access the live webcast through the company's website under the 'Investors' section. Prestige Consumer Healthcare distributes various well-known consumer healthcare products including Monistat®, Summer’s Eve®, and Dramamine®. The firm's diverse portfolio serves retail markets in the U.S., Canada, Australia, and other international locations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced that it will release its fiscal 2023 third quarter earnings on February 2, 2023, before the market opens. A conference call to discuss these results will take place at 8:30 a.m. ET on the same day. Investors can join the call via a live Internet webcast or by phone after registering. A replay of the call will be available for one week afterward. This earnings report is pivotal for stakeholders to gauge the company’s financial health and performance metrics.
Prestige Consumer Healthcare (NYSE:PBH) reported Q2 fiscal 2023 revenue of $289.3 million, a 4.7% increase over the previous year, and earnings per share (EPS) of $1.02, surpassing expectations. The company reduced its debt by $35 million, achieving a leverage ratio of 3.7x. For the first half of fiscal 2023, revenue reached $566.3 million, up 3.8%. The company reaffirmed its fiscal 2023 revenue outlook of $1,120 to $1,130 million and EPS guidance of $4.18 to $4.23, amidst ongoing supply chain challenges.
Prestige Consumer Healthcare (NYSE:PBH) announced its fiscal 2023 Q2 earnings release on November 3, 2022, prior to market opening. The company will conduct a conference call at 8:30 a.m. ET on the same day to discuss the earnings results. Investors can join the live webcast via the Investor Relations page on their website or register for phone participation to receive dial-in details. A replay of the conference call will be available for one week post-event.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will present at the 2022 Barclays Global Consumer Staples Conference on September 8, 2022, at 12:45 p.m. ET. Interested parties can access a live webcast via the company's website in the 'Investors' section. For those unable to attend the live session, a replay will be available afterward.
Prestige Consumer Healthcare offers a diverse range of products including Monistat®, Summer’s Eve®, BC®, and many more, catering to consumers across the U.S., Canada, Australia, and other international markets.
Prestige Consumer Healthcare (NYSE: PBH) reported Q1 fiscal 2023 revenue of $277.1 million, marking a 2.9% increase year-over-year. Diluted EPS stood at $1.09, exceeding expectations, while net income reached $55.3 million. Cash flow from operations was $58.2 million, with free cash flow at $57.2 million. The company reaffirmed its fiscal 2023 revenue outlook of $1.12 to $1.13 billion and EPS guidance of $4.18 to $4.23. Strategic share repurchase actions and debt reduction were highlighted as key focuses amid a challenging operating environment.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2023 Q1 earnings on August 4, 2022, before market opening. A conference call to discuss the results will follow at 8:30 a.m. ET, accessible via the company's website. Participants can join through phone by dialing U.S./Canada: 833-634-2598 or internationally: 412-902-4108. A replay will be available for a week post-call using conference ID 9498360. The company markets a wide range of consumer healthcare products across North America and internationally.
Prestige Consumer Healthcare (PBH) reported strong financial results for fiscal 2022, with Q4 revenue of $266.9 million (up 12.3%) and full-year revenue of $1,086.8 million (up 15.2%). Adjusted diluted EPS for the year was $4.06 (up 25.3%). The company generated $259.9 million in net cash from operations, with record free cash flow of $253.7 million. The board authorized a $50 million share repurchase program. For fiscal 2023, PBH forecasts revenues between $1,120 million to $1,130 million, expecting organic growth of 2% to 3%.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will issue its fiscal 2022 fourth quarter and year-end earnings on May 5, 2022, after market close. A conference call is scheduled for May 6 at 8:30 a.m. ET to discuss the results and company performance. Interested participants can join via phone or through an online webcast available on the company's Investor Relations page. Telephonic replays are accessible for a week post-call. Prestige Consumer Healthcare markets a variety of health products across North America and other markets.
Prestige Consumer Healthcare (NYSE:PBH) reported a 14.9% revenue increase to $274.5 million in Q3 2022, with a 22.2% rise in diluted EPS to $0.99. Nine-month revenues reached $819.9 million, up 16.2%. The company raised its full-year outlook, projecting revenue between $1,075 and $1,080 million, and adjusted EPS of $4.00 to $4.04. Strong performance stemmed from key brands, with increased demand in COVID-affected categories. Free cash flow for the quarter was $64.1 million, aiding in debt reduction.
